Sugi Predict

Sugi Predict / Compounds / SCHEMBL90071

SCHEMBL90071

SCHEMBL90071

CC1(C)CNc2cc([N+](=O)[O-])ccc2O1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ AKR1B1 P15121 1/20 0.45
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ NR3C1 P04150 2/20 0.40
▸ PGR P06401 2/20 0.40
▸ AR P10275 2/20 0.40
▸ ALPL P05186 1/20 0.40
▸ CAPN9 O14815 1/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ ALDH1A1 P00352 5/20 0.39
▸ TDP1 Q9NUW8 3/20 0.39
▸ MALT1 Q9UDY8 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ CYP3A4 P08684 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ NR3C2 P08235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9143251 0.88 MAPT (0.50) MAPTNPC1RAB9AAKR1B1MEN1
SCHEMBL8801204 0.80 MAPT (0.46) MAPTNPC1RAB9AAKR1B1MEN1
SCHEMBL8799331 0.78 MAPT (0.44) MAPTNPC1RAB9AAKR1B1MEN1
SCHEMBL15322027 0.77 MAPT (0.42) MAPTNPC1RAB9AAKR1B1MEN1
SCHEMBL9145032 0.76 KDM4E (0.38) AKR1B1KDM4E
SCHEMBL430140 0.76 HSD17B10 (0.50) MAPTKMT2APGRALDH1A1CYP3A4
SCHEMBL9143227 0.75 CYP1A2 (0.39) MAPTNPC1RAB9AAKR1B1ALDH1A1
SCHEMBL20511231 0.75 KDM4E (0.37) MAPTMEN1KMT2AKDM4E
SCHEMBL2721900 0.74 MAPT (0.48) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL3586235 0.74 MAPT (0.49) MAPTMEN1KMT2AALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110746424-A MK2 inhibitors and uses thereof 西建卡尔有限责任公司 2020-02-04 — — CN disclosed
US-20190135835-A1 MK2 INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2019-05-09 — — US disclosed
US-10138256-B2 MK2 inhibitors and uses thereof CELGENE CAR LLC (BM) 2018-11-27 — — US disclosed
EP-2968339-A1 MK2 INHIBITORS AND USES THEREOF Celgene Avilomics Research, Inc. (US) 2016-01-20 — — EP disclosed
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2015-12-31 — — US disclosed
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2015-12-31 — — US disclosed
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2015-12-31 — — US disclosed
WO-2014149164-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-09-25 — — WO disclosed
WO-2014149164-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-09-25 — — WO disclosed
US-8642624-B2 Substituted alkylamine derivatives and methods of use AMGEN INC. (US) 2014-02-04 — — US disclosed
US-6995162-B2 Substituted alkylamine derivatives and methods of use AMGEN INC. (US) 2006-02-07 — — US disclosed
WO-2006012374-A1 SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2006-02-02 — — WO disclosed
WO-2000012492-A1 BENZOXAZINE DERIVATIVES NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2000-03-09 — — WO disclosed
CN-1029479-C Process for preparing benzoxazine derivatives YAMANOUCHI PHARMACEUTICAL KK (JP) 1995-08-09 — — CN disclosed
US-5420126-A Potassium channel activators YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1995-05-30 — — US disclosed
CN-1100423-A Novel derivative of benoxazine and pharmaceutical composition containing same YAMANOUCHI PHARMA CO LTD (JP) 1995-03-22 — — CN disclosed
CN-1100422-A Novel derivative of benoxazine and pharmaceutical composition containing same YAMANOUCHI PHARMA CO LTD (JP) 1995-03-22 — — CN disclosed
EP-0500319-A1 Oxazinobenzazole compounds YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1992-08-26 — — EP disclosed
EP-0432893-A2 Benzoxazine derivatives, their preparation and pharmaceutical compositions containing them YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1991-06-19 — — EP disclosed
CN-1051910-A Benzoxazine derivatives and pharmaceutical compositions containing them YAMANOUCHI PHARMRCEUTICAL (JP) 1991-06-05 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, DUSP2, MKNK1 MAPT 2354/4885NPC1 3265/4885RAB9A 3788/4885
US-10138256-B2 MK2 inhibitors and uses thereof MKNK2, DUSP2, MKNK1 MAPT 2354/4885NPC1 3265/4885RAB9A 3788/4885
US-20190135835-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, DUSP2, MKNK1 MAPT 2354/4885NPC1 3265/4885RAB9A 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.